Recent news and posts
MTRC released a White Paper assessing evidence requirements of the NICE's early value assessment (EVA) program in the UK
Health technology assessment plays an important role in market access for medical technologies in England.
NICE's early value assessment (EVA) program in medical technology, launched in 2022, assesses mostly digital technologies at an early stage in evidence generation.
The program recommends the most promising technologies for use in the NHS while further evidence is being generated. NICE focuses on clinical effectiveness, safety, cost, and cost-effectiveness of the technologies.
In this White Paper, MTRC performed a review of five recent EVA assessments by NICE to present the evidence requirements for digital and diagnostic medical technologies in this particular HTA program.
A review of five cases is followed by recommendations in relation to evidence generation for medical technologies, market access in England, and factors influencing the decision-making of NICE.
Read more and request access to the White Paper here.